genetic-epilepsy | Media Room | PressRelease.com

Tagged genetic-epilepsy

Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of Patients With Dravet Syndrome

Press Release Aug 23, 2017

Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of Patients With Dravet Syndrome

Dravet Syndrome is a catastrophic form of epilepsy, affecting one in 15,700 children and adults in the United States. Read More

Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome

Press Release Apr 25, 2017

Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome

Dravet Syndrome, a catastrophic form of epilepsy, affects one in 15,700 children and adults in the United States. Read More

First
Prev

1

Next
Last